{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:01:23Z","timestamp":1780203683098,"version":"3.54.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178187","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T06:46:40Z","timestamp":1758869200000},"page":"178187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mapping the evolving landscape of lecanemab research in Alzheimer's Disease: A bibliometric analysis"],"prefix":"10.1016","volume":"1006","author":[{"given":"Xu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178187_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's Disease: a systematic review and meta-analysis","volume":"104","author":"Arroyo-Pacheco","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178187_bib2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/bcp.70021","article-title":"Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's Disease: the pharmacovigilance perspective","volume":"91","author":"Bobbins","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178187_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178187_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223994","article-title":"Visualizing a field of research: a methodology of systematic scientometric reviews","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178187_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's Disease: strategies and research directions","author":"Cummings","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178187_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s11192-015-1645-z","article-title":"The bibliometric analysis of scholarly production: how great is the impact?","volume":"105","author":"Ellegaard","year":"2015","journal-title":"Scientometrics"},{"key":"10.1016\/j.ejphar.2025.178187_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102471","article-title":"Emerging microglial biology highlights potential therapeutic targets for Alzheimer's Disease","volume":"101","author":"Fan","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178187_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/09727531231187235","article-title":"Breakthroughs in Alzheimer's research: a path to a more promising future?","volume":"31","author":"Fatima","year":"2024","journal-title":"Ann. Neurosci."},{"key":"10.1016\/j.ejphar.2025.178187_bib9","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.2147\/DDDT.S518489","article-title":"Bibliometrics analysis and knowledge mapping of fragment-based drug design research: trends from 2015 to 2024","volume":"19","author":"He","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178187_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","article-title":"Lecanemab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.178187_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100195","article-title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","author":"Hsu","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"20","key":"10.1016\/j.ejphar.2025.178187_bib12","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","article-title":"Alzheimer's Disease: from immunotherapy to immunoprevention","volume":"186","author":"Jucker","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178187_bib13","article-title":"Emerging roles of adaptive immune response in Alzheimer's Disease","author":"Li","year":"2024","journal-title":"Aging Dis"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178187_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/10807039.2010.501248","article-title":"A bibliometric study of the trend in articles related to risk assessment published in science citation index","volume":"16","author":"Mao","year":"2010","journal-title":"Human and Ecological Risk Assessment"},{"issue":"7","key":"10.1016\/j.ejphar.2025.178187_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209218","article-title":"Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer Disease","volume":"102","author":"Nguyen","year":"2024","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ejphar.2025.178187_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103677","article-title":"Global biomarker trends in Alzheimer's research: a bibliometric analysis","volume":"28","author":"Noda","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178187_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14712598.2025.2463963","article-title":"Successes and failures: the latest advances in the clinical development of amyloid-\u03b2-targeting monoclonal antibodies for treating Alzheimer's Disease","volume":"25","author":"Panza","year":"2025","journal-title":"Expet Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178187_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JAD-210525","article-title":"Connecting cohorts to diminish Alzheimer's Disease (CONCORD-AD): a report of an international research collaboration network","volume":"85","author":"Pavlik","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2025.178187_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1169499","article-title":"Safety and efficacy of lecanemab for Alzheimer's Disease: a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Qiao","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178187_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's Disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178187_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13430","article-title":"BACE1: more than just a \u03b2-secretase","volume":"23","author":"Taylor","year":"2022","journal-title":"Obes. Rev."},{"key":"10.1016\/j.ejphar.2025.178187_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.804177","article-title":"A bibliometric review on gut microbiome and Alzheimer's Disease between 2012 and 2021","volume":"14","author":"Trejo-Castro","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178187_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178187_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178187_bib25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s11192-017-2300-7","article-title":"Citation-based clustering of publications using CitNetExplorer and VOSviewer","volume":"111","author":"van Eck","year":"2017","journal-title":"Scientometrics"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178187_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17582024.2024.2435250","article-title":"Effectiveness of neuro-feedback on Alzheimer's rehabilitation: a bibliometric analysis","volume":"14","author":"Verma","year":"2024","journal-title":"Neurodegener. Dis. Manag."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178187_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer Disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2025.178187_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1439055","article-title":"A review of the roles of pathogens in Alzheimer's disease","volume":"18","author":"Zhao","year":"2024","journal-title":"Front. Neurosci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:36:48Z","timestamp":1780202208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"alternative-id":["S0014299925009410"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178187","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the evolving landscape of lecanemab research in Alzheimer's Disease: A bibliometric analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178187"}}